Yorktown Management & Research CO Inc Intellia Therapeutics, Inc. Transaction History

Yorktown Management & Research CO Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$33.21 - $62.69 $87,010 - $164,247	-2,620 Reduced 17.1%	12,700 $0
Q2 2022 Jul 29, 2022	SELL	$38.49 - $76.21 $76,980 - $152,420	-2,000 Reduced 11.55%	15,320 $793,000
Q1 2022 Apr 29, 2022	SELL	$58.27 - $118.99 $115,374 - $235,600	-1,980 Reduced 10.26%	17,320 $1.26 Million
Q4 2021 Feb 09, 2022	BUY	$100.76 - $138.36 $100,760 - $138,360	1,000 Added 5.46%	19,300 $2.28 Million
Q3 2021 Nov 04, 2021	BUY	$132.37 - $176.78 $79,422 - $106,068	600 Added 3.39%	18,300 $2.46 Million
Q2 2021 Aug 03, 2021	BUY	$60.88 - $161.91 $103,496 - $275,247	1,700 Added 10.63%	17,700 $2.87 Million
Q1 2021 May 11, 2021	BUY	$46.59 - $83.68 $46,590 - $83,680	1,000 Added 6.67%	16,000 $1.28 Million
Q4 2020 Feb 11, 2021	SELL	$18.83 - $63.53 $18,830 - $63,530	-1,000 Reduced 6.25%	15,000 $816,000
Q3 2020 Nov 06, 2020	BUY	$17.47 - $24.93 $48,916 - $69,804	2,800 Added 21.21%	16,000 $318,000
Q2 2020 Aug 11, 2020	BUY	$11.14 - $22.87 $147,048 - $301,884	13,200 New	13,200 $277,000

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Yorktown Management & Research CO Inc, based on Form 13F filings with the SEC.

Stay updated on Yorktown Management & Research CO Inc with notifications on news.